CCND1 amplification has been observed in 20–38% of melanoma samples, which indicates that a large group of patients is potentially resistant to BRAFi and could benefit from treatment with a CDK4/6 inhibitor [84,85,86]. The gene discussed is CDK4; the disease is melanoma.